Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
The effect of novel D3 use as a mouthwash in COVID-19 patients	King Faisal Specialist Hospital & Research Centre Jeddah, Saudi Arabia	Ongoing	Cholecalciferol (vitamin D)	3	2022-32	King Faisal Specialist Hospital and Research Center (Jeddah)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension	Astrazeneca	Ongoing	Baxdrostat	3	D6970C00009	King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO  TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER	Roche	Ongoing	Giredestrant , Phesgo	3	WO43571	King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh)
Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial	King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia	Ongoing	Bismuth Subcitrate Potassium , Tetracycline , Metronidazol	2	2231295	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism	Rezolute Inc	Ongoing	RZ358	3	RZ358-301	King Abdulaziz Medical City NG (Riyadh)
A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1	Cyclo Therapeutics, Inc	Ongoing	Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™)	3	CTD-TCNPC-301	King Faisal Specialist Hospital and Research Center (Riyadh)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study	King Abdullah International Medical Research Center (KAIMRC)	Rejected	BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine	2	RJ19/119/J	King Abdulaziz Medical City NG (Jeddah)
REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line.	Bayer Saudi Arabia LLC	Ongoing	ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib,	4	22453	King Faisal Specialist Hospital and Research Center (Jeddah)
A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia	Sanofi	Ongoing	iGlarLixi	4	OBS17984	King Fahad Medical City (Riyadh)
PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING	Roche	Ongoing	emicizumab	4	MO401001	King Abdulaziz Medical City NG (Jeddah)